Journal
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume 44, Issue 3, Pages 358-365Publisher
TAYLOR & FRANCIS AS
DOI: 10.1080/00365520802530861
Keywords
Fibrosing steatohepatitis; hepatic stellate cells; non-alcoholic steatohepatitis; peroxisome proliferator activated receptor gamma; rosiglitazone
Categories
Funding
- Wang Bao-en Foundation [20070021]
- Council Competitive Earmarked Research [CUHK 478207]
Ask authors/readers for more resources
Objective. Currently, no agent has been confirmed as preventing the fibrosing progression of non-alcoholic steatohepatitis (NASH). In this study, rosiglitazone was used in the clinical treatment of insulin resistance in patients with type 2 diabetes mellitus. However, its protective effect on non-alchoholic fibrosing steatohepatitis is not clear. The study aimed to elucidate the effect and the mechanism of rosiglitazone in inhibiting nutrition-related fibrosis in mice. Methods. C57BL6/J mice were fed a high fat, methionine-choline deficient (MCD) diet for 8 weeks to induce hepatic fibrosis, and rosiglitazone was given in the treated group. The effect of rosiglitazone was assessed by comparing the severity of hepatic fibrosis in liver sections, the activation of hepatic stellate cells (HSCs) and the expression of TGF-1 and connective tissue growth factor (CTGF). Results. At week 8, MCD-diet-induced fibrosing NASH models showed increased serum ALT and AST levels, severe hepatic steatosis, and infiltration of inflammation and fibrosis which, associated with down-regulated PPAR mRNA and protein expression, up-regulated -SMA protein expression and enhanced TGF-1, CTGF mRNA and protein expression. Rosiglitazone significantly lowered serum ALT and AST and it reduced MCD-induced fibrosis by repressing levels of -SMA protein expression and pro-fibrosis factors TGF-1 and CTGF. It also restored expression of PPAR. Conclusions. The present study provides clear morphological and molecular biological evidence of the protective role of rosiglitazone in ameliorating nutritional fibrosing steatohepatitis. Rosiglitazone may ameliorate hepatic fibrosis by activating PPAR, which can inhibit HSC activation and suppress TGF-1 and CTGF expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available